Decreased cortical muscarinic M1 receptors in schizophrenia are associated with changes in gene promoter methylation, mRNA and gene targeting microRNA

Translational Psychiatry

Volumn 3, Issue , 2013, Pages

  Scarr, E ^a   Craig, J M ^a,b   Cairns, M J ^c,d   Seo, M S ^a   Galati, J C ^b,e   Beveridge, N J ^c,d   Gibbons, A ^a   Juzva, S ^a   Weinrich, B ^b   Parkinson Bates, M ^a   Carroll, A P ^c,d   Saffery, R ^a   Dean, B ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

^c HUNTER MEDICAL RESEARCH INSTITUTE   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e LA TROBE UNIVERSITY   (Australia)

Author keywords

CHRM1; cortex; muscarinic M1 receptor; postmortem CNS; schizophrenia

Indexed keywords

MESSENGER RNA; MICRORNA; MUSCARINIC M1 RECEPTOR; CHRM1 PROTEIN, HUMAN; MIRN107 MICRORNA, HUMAN; MUSCARINIC RECEPTOR;

ADULT; ARTICLE; BRAIN CORTEX; CLINICAL ARTICLE; FEMALE; GENE TARGETING; HUMAN; IN VITRO STUDY; MALE; METHYLATION; NEUROBIOLOGY; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; SCHIZOPHRENIA; CLASSIFICATION; COHORT ANALYSIS; DNA METHYLATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROMOTER REGION; PSYCHOLOGICAL ASPECT;

ADULT; CEREBRAL CORTEX; COHORT STUDIES; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION; GENE TARGETING; HUMANS; MALE; MICRORNAS; MIDDLE AGED; PROMOTER REGIONS, GENETIC; RECEPTORS, MUSCARINIC; RNA, MESSENGER; SCHIZOPHRENIA;

EID: 84874295049     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2013.3     Document Type: Article

References (48)

1. Tamminga CA. Accelerating new knowledge in schizophrenia. Am J Psychiatry 2008; 165: 949-951.
2. Raedler TJ, Bymaster FP, Tandon R, Copolov D, Dean B. Towards a muscarinic hypothesis of schizophrenia. Mol Psychiatry 2007; 12: 232-246.
3. Scarr E, Cowie TF, Kanellakis S, Sundram S, Pantelis C, Dean B. Decreased cortical muscarinic receptors define a subgroup of subjects with schizophrenia. Mol Psychiatry 2009; 14: 1017-1023.
4. Scarr E, Dean B. Muscarinic receptors: do they have a role in the pathology and treatment of schizophrenia? J Neurochem 2008; 107: 1188-1195.
5. Gibbons AS, Scarr E, Boer S, Money T, Jeon WJ, Felder C et al. Widespread decreases in cortical muscarinic receptors in a subset of people with schizophrenia. Int J Neuropsychopharmacol; S1461145712000028 [pii]; doi:10.1017/S1461145712000028 (in press).
6. Dean B, McLeod M, Keriakous D, McKenzie J, Scarr E. Decreased muscarinic(1) receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol Psychiatry 2002; 7: 1083-1091.
7. Scarr E, Keriakous D, Crossland N, Dean B. No change in cortical muscarinic M2, M3 receptors or [35S]GTPgammaS binding in schizophrenia. Life Sci 2006; 78: 1231-1237.
8. Hill C, Keks N, Roberts S, Opeskin K, Dean B, Mackinnon A et al. Problem of diagnosis in postmortem brain studies of schizophrenia. Am J Psychiatry 1996; 153: 533-537.
9. Roberts SB, Hill CA, Dean B, Keks NA, Opeskin K, Copolov DL. Confirmation of the diagnosis of schizophrenia after death using DSM-IV: a Victorian experience. Aust N Z J Psychiatry 1998; 32: 73-76.
10. Remington GJ. Antipsychotics (Neuroleptics). In B-Bjai JJ (ed) Handbook of Psychotropic Drugs. Hogrefe & Huber: Seattle, Toronto, Gottingen, Bern, 1999, pp 55-84.
11. Dean B, Pavey G, Chai SY, Mendelsohn FAO. The localisation and quantification of molecular changes in the human brain using in situ radioligand binding and autoradiography. In Dean B, Kleinman JE, Hyde TM (ed) Using CNS tissue in psychiatric research: A practical guide. Harwood Academic Press: Amsterdam, 1999, pp 67-83.
12. Stan AD, Ghose S, Gao XM, Roberts RC, Lewis-Amezcua K, Hatanpaa KJ et al. Human postmortem tissue: what quality markers matter? Brain Res 2006; 1123: 1-11.
13. Kingsbury AE, Foster OJ, Nisbet AP, Cairns N, Bray L, Eve DJ et al. Tissue pH as an indicator of mRNA preservation in human post-mortem brain. Brain Res Mol Brain Res 1995; 28: 311-318.
14. Ollikainen M, Smith KR, Joo EJ, Ng HK, Andronikos R, Novakovic B et al. DNA methylation analysis of multiple tissues from newborn twins reveals both genetic and intrauterine components to variation in the human neonatal epigenome. Hum Mol Genet 2010; 19: 4176-4188.
15. Ewing B, Green P. Base-calling of automated sequencer traces using phred. II. Error probabilities. Genome Res 1998; 8: 186-194.
16. Fraga MF, Esteller M. DNA methylation: a profile of methods and applications. Biotechniques 2002; 33: 632, 634, 636-649.
17. Scarr E, Sundram S, Keriakous D, Dean B. Altered hippocampal muscarinic m4, but not m1, receptor expression from subjects with schizophrenia. Biol Psychiatry 2007; 61: 1161-1170.
18. Loiacono RE, Gundlach AL. In situ hybridisation histochemistry: application to human brain tissue. In Dean B, Hyde TM, Kleinman JE (ed) Using CNS Tissue in Psychiatric Research: A Practical Guide. Harwood Academic Press: Sydney, 1999, pp 85-106.
19. Dean B, Pavey G, Opeskin K. [3H]raclopride binding to brain tissue from subjects with schizophrenia: methodological aspects. Neuropharmacology 1997; 36: 779-786.
20. Megraw M, Sethupathy P, Corda B, Hatzigeorgiou AG. miRGen: a database for the study of animal microRNA genomic organization and function. Nucleic Acids Res 2007; 35: D149-D155.
21. Udawela M, Scarr E, Hannan AJ, Thomas EA, Dean B. Phospholipase C beta 1 expression in the dorsolateral prefrontal cortex from patients with schizophrenia at different stages of illness. Aust N Z J Psychiatry 2011; 45: 140-147.
22. Santarelli DM, Beveridge NJ, Tooney PA, Cairns MJ. Upregulation of dicer and microRNA expression in the dorsolateral prefrontal cortex Brodmann area 46 in schizophrenia. Biol Psychiatry 2011; 69: 180-187.
23. Beveridge NJ, Gardiner E, Carroll AP, Tooney PA, Cairns MJ. Schizophrenia is associated with an increase in cortical microRNA biogenesis. Mol Psychiatry 2010; 15: 1176-1189.
24. Beveridge NJ, Tooney PA, Carroll AP, Tran N, Cairns MJ. Down-regulation of miR-17 family expression in response to retinoic acid induced neuronal differentiation. Cell Signal 2009; 21: 1837-1845.
25. D'Agostino RB, Belanger A, D'Agostino RB Jnr. A suggestion for using powerful and informative tests of normality. Am Stat 1990; 44: 316-321.
26. Cook RD, Weisberg S. Applied Regression Including Computing and Graphics. Wiley: Hoboken, 2011.
27. Dean B, Boer S, Gibbons A, Money T, Scarr E. Recent advances in postmortem pathology and neurochemistry in schizophrenia. CurrOpin Psychiatry2009; 22:154-160.
28. Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Moller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia. World J Biol Psychiatry 2005; 6:132-191.
29. Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B. Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment. Am J Psychiatry 2001; 158: 918-925.
30. Zavitsanou K, Katsifis A, Filomena M, Xu-Feng H. Investigation of M1/M4 muscarinic receptors in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression disorder. Neuropsychopharmacology 2004; 29: 619-625.
31. Deng C, Huang XF. Decreased density of muscarinic receptors in the superior temporal gyrus in schizophrenia. J Neurosci Res 2005; 81: 883-890.
32. Newell KA, Zavitsanou K, Jew SK, Huang XF. Alterations of muscarinic and GABA receptor binding in the posterior cingulate cortex in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 225-233.
33. Mancama D, Arranz MJ, Landau S, Kerwin R. Reduced expression of the muscarinic 1 receptor cortical subtype in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2003; 119: 2-6.
34. Turker MS. Gene silencing in mammalian cells and the spread of DNA methylation. Oncogene 2002; 21: 5388-5393.
35. Melas PA, Rogdaki M, Osby U, Schalling M, Lavebratt C, Ekstrom TJ. Epigenetic aberrations in leukocytes of patients with schizophrenia: association of global DNA methylation with antipsychotic drug treatment and disease onset. FASEB J 2012; 26: 2712-2718.
36. Qureshi IA, Mehler MF. The emerging role of epigenetics in stroke: II. RNA regulatory circuitry. Arch Neurol 2010; 67:1435-1441.
37. Huang HS, Akbarian S. GAD1 mRNA expression and DNA methylation in prefrontal cortex of subjects with schizophrenia. PLoS ONE 2007; 2: e809.
38. Iwamoto K, Bundo M, Yamada K, Takao H, Iwayama-Shigeno Y, YoshikawaT et al. DNA methylation status of SOX10 correlates with its downregulation and oligodendrocyte dysfunction in schizophrenia. J Neurosci 2005; 25: 5376-5381.
39. Grayson DR, Chen Y, Costa E, Dong E, Guidotti A, Kundakovic M et al. The human reelin gene: transcription factors (+) , repressors (-) and the methylation switch (+/-) in schizophrenia. Pharmacol Ther 2006; 111: 272-286.
40. Veldic M, Caruncho HJ, Liu WS, Davis J, Satta R, Grayson DR et al. DNA-methyltransferase 1 mRNA is selectively overexpressed in telencephalic GABAergic interneurons of schizophrenia brains. Proc Natl Acad Sci USA 2004; 101: 348-353.
41. Abdolmaleky HM, Yaqubi S, Papageorgis P, Lambert AW, Ozturk S, Sivaraman V et al. Epigenetic dysregulation of HTR2A in the brain of patients with schizophrenia and bipolar disorder. Schizophr Res 2011; 129:183-190.
42. Garrick D, Fiering S, Martin DI, Whitelaw E. Repeat-induced gene silencing in mammals. Nat Genet 1998; 18: 56-59.
43. Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet 2003; 33(Suppl): 245-254.
44. Puckett RE, Lubin FD. Epigenetic mechanisms in experience-driven memory formation and behavior. Epigenomics 2011; 3: 649-664.
45. Conn PJ, Christopoulos A, Lindsley CW. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Discov 2009; 8: 41-54.
46. Jones CK, Brady AE, Davis AA, Xiang Z, Bubser M, Tantawy MN et al. Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats. J Neurosci 2008; 28: 10422-10433.
47. Raedler TJ, Knable MB, Jones DW, Urbina RA, Gorey JG, Lee KS et al. In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia. Am J Psychiatry 2003; 160:118-127.
48. Insel TR. Disruptive insights in psychiatry: transforming a clinical discipline. J Clin Invest 2009; 119: 700-705.